Mechanistic studies to understand the inhibition of wildtype and mutant HIV-1 reverse transcriptase by carbovir-triphosphate

被引：11

作者：

Ray, AS ^{[1
]}

Anderson, KS ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA

来源：

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 2001年 / 20卷 / 4-7期

关键词：

D O I：

10.1081/NCN-100002528

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Abacavir (1592U89) has recently been approved by the FDA for treatment of HIV infection. Transient kinetic studies were carried out to better understand the interaction of the active metabolite of Abacavir (Carbovir-triphosphate) with wild type and mutant HIV-1 reverse transcriptase. Some of the data is summarized and used as a basis for discussion of inhibition by CBVTP and previously studied nucleoside analogs.

引用

页码：1247 / 1250

页数：4

共 9 条

[1] 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity [J].

Daluge, SM ;

Good, SS ;

Faletto, MB ;

Miller, WH ;

StClair, MH ;

Boone, LR ;

Tisdale, M ;

Parry, NR ;

Reardon, JE ;

Dornsife, RE ;

Averett, DR ;

Krenitsky, TA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1082-1093

[2] Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase [J].

Feng, JY ;

Anderson, KS .

BIOCHEMISTRY, 1999, 38 (01) :55-63

[3]

JOHNSON BL, 1992, J EXPO ANAL ENV EPID, V1, P1

[4] Substrates of DNA polymerases with planar conformation of sugar: model of substrate transition state? [J].

Krayevsky, AA ;

Watanabe, KA .

NUCLEOSIDES & NUCLEOTIDES, 1998, 17 (07) :1153-1162

[5] POTENTIAL MECHANISM FOR SUSTAINED ANTIRETROVIRAL EFFICACY OF AZT-3TC COMBINATION THERAPY [J].

LARDER, BA ;

KEMP, SD ;

HARRIGAN, PR .

SCIENCE, 1995, 269 (5224) :696-699

[6] METABOLISM OF CARBOVIR, A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1, AND ITS EFFECTS ON CELLULAR-METABOLISM [J].

PARKER, WB ;

SHADDIX, SC ;

BOWDON, BJ ;

ROSE, LM ;

VINCE, R ;

SHANNON, WM ;

BENNETT, LL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1004-1009

[7] Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89 [J].

Tisdale, M ;

Alnadaf, T ;

Cousens, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1094-1098

[8] Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTP [J].

Vaccaro, JA ;

Parnell, KM ;

Terezakis, SA ;

Anderson, KS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :217-221

[9] POTENT AND SELECTIVE ACTIVITY OF A NEW CARBOCYCLIC NUCLEOSIDE ANALOG (CARBOVIR-NSC-614846) AGAINST HUMAN IMMUNODEFICIENCY VIRUS INVITRO [J].

VINCE, R ;

HUA, M ;

BROWNELL, J ;

DALUGE, S ;

LEE, FC ;

SHANNON, WM ;

LAVELLE, GC ;

QUALLS, J ;

WEISLOW, OS ;

KISER, R ;

CANONICO, PG ;

SCHULTZ, RH ;

NARAYANAN, VL ;

MAYO, JG ;

SHOEMAKER, RH ;

BOYD, MR .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 156 (02) :1046-1053

← 1 →